Clinical risk factors for Clostridium difficile-associated diseases

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 3, 2012, Pages 256-261

  Min Cho, Sung ^a   Joon Lee, Jae ^a   Jung Yoon, Hee ^a  

^a Eulji University   (South Korea)

Author keywords

Clostridium difficile associated diseases; Risk factors

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROLIDE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE; ARTICLE; CHRONIC LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FEMALE; GENDER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ILEUS; INFECTION RISK; INTENSIVE CARE UNIT; KOREA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; SURGERY; WARD;

CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; HUMANS; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84862006428     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70320-3     Document Type: Article

References (36)

1. Gorbach S.L. Antibiotics and Clostridium difficile. N Engl J Med 1999, 341:1690-1691.
2. Gaynes R., Rimland D., Killum E., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004, 38:640-645.
3. McCusker M.E., Harris A.D., Perencevich E., Roghmann M.C. Fluoroquinolone use and Clostridium difficile associated diarrhea. Emerg Infect Dis 2003, 9:730-733.
4. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
5. Golledge C.L., Carson C.F., O'Neill G.L., Bowman R.A., Riley T.V. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1992, 30:141-147.
6. Alonso R., Pelaez T., Gonzalez-Abad M.J., et al. In vitroactivity of new quinolones against Clostridium difficile. J Antimicrob Chemother 2001, 47:195-197.
7. Gerding D.N., Johnson S., Peterson L.R., Mulligan M.E., Silva J. SHEA position paper: Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995, 16:459-477.
8. Anand A., Bashey B., Mir T., Glatt A.E. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994, 89:519-523.
9. Jones E.M., Kirkpatrick B.L., Feeney R., Reeves D.S., MacGowan A.P. Hospital-acquired Clostridium difficile diarrhea. Lancet 1997, 349:1176-1177.
10. Walker K.J., Gilliland S.S., Vance-Bryan K., et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993, 41:940-946.
11. Simor A.E., Bradley S.F., Strausbaugh L.J., et al. Clostridium difficile in long-term care facilities for the elderly. Infect Control Hosp Epidemiol 2002, 23:696-703.
12. Bliss D.Z., Johnson S., Savik K., Clabots C.R., Willard K., Gerding D.N. Acquisition of Clostridium difficile and Clostridium difficile associated diarrhea in hospitalized patients receiving tube feeding. Ann Int Med 1998, 129:1012-1019.
13. Kyne L., Sougioultzis S., McFarland L.V., Kelly C.P. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epi 2002, 23:653.
14. Horn S.D., Sharkey P.D., Bertram D.A. Measuring severity of illness: homogeneous case mix groups. Med Care 1983, 21:14-30.
15. Garey K.W., Sethi S., Yadav Y., DuPont H.L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. Journal of Hospital Infection 2008, 70:298-304.
16. Riley T.V., Cooper M., Bell B., Golledge C.L. Community-acquired Clostridium difficile-associated diarrhea. Clin Infect Dis 1995, 20:S263-S265.
17. Lee J.H., Lee S.Y., Kim Y.S., et al. The incidence and clinical features of Clostridium difficile infection; single center study. J Korean Gastroenterol 2010, 55:175-182.
18. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infection. 2009, 58:403-410.
19. Kurd M.F., Pulido L., Joshi A., Purtill J.J., Parvizi J. Clostridium difficile infection after total joint arthroplasty: who is at risk?. J Arthroplasty 2008, 23:839-842.
20. Bruns A.H., Oosterheert J.J., Kuijper E.J., et al. Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile. J Antimicrob Chemother 2010, 65:2464-2471.
21. Debast S.B., Vaessen N., Choudry A., Wiegers-Ligtvoet E.A., van den Berg R.J., Kuijper E.J. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009, 15:427-434.
22. Hu M.Y., Maroo S., Kyne L., et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol 2008, 6:1354-1360.
23. Henrich T.J., Krakower D., Bitton A., Yokoe D.S. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-422.
24. Bishara J., Peled N., Pitlik S., Samra Z. Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile. J Hosp Infect 2008, 68:308-314.
25. Cloud J., Noddin L., Pressman A., Hu M., Kelly C. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 2009, 7:868-873.
26. Curry S.R., Marsh J.W., Shutt K.A., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48:425-429.
27. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009, 15:281-284.
28. Tokars J.I., Satake S., Rimland D., et al. The prevalence of colonization with vancomycin-resistant Enterococcus at a veterans' affairs institution. Infect Control Hosp Epidemiol 1999, 20:171-175.
29. Rafferty M.E., McCormick M.I., Bopp L.H., et al. Vancomycinresistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997, 18:342-344.
30. Sonnenberg A. Similar geographic variations of mortality and hospitalization associated with IBD and Clostridium difficile colitis. Inflamm Bowel Dis 2000, 16:487-493.
31. Drew R.J., Boyle B. RUWA scoring system: a novel predictive tool for the identification of patients at high risk for complications from Clostridium difficile infection. J Hosp Infect 2009, 71:93-94.
32. Bhangu A., Czapran A., Bhangu S., Pillay D. Optimum timing of blood tests for monitoring patients with Clostridium difficile associated diarrhea. J Investig Med 2010, 58:621-624.
33. Hu M.Y., Katchar K., Kyne L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009, 136:1206-1214.
34. Howitt J.R., Grace J.W., Schaefer M.G., Dolder C., Cannella C., Schaefer R.S. Clostridium difficile-positive stools: a retrospective identification of risk factors. Am J Infect Control 2008, 36:488-491.
35. Ryan J., Murphy C., Twomey C., et al. Asymptomatic carriage of Clostridium difficile in an Irish continuing care institution for the elderly: prevalence and characteristics. Ir J Med Sci 2010, 179:245-250.
36. Lee B.Y., Popovich M.J., Tian Y., et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010, 28:5245-5253.